Lilotomab (formerly tetulomab, HH1) is a murine monoclonal antibody against CD37, a glycoprotein which is expressed on the surface of mature human B cells. It was generated at the Norwegian Radium Hospital.
As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA. This compound is called 177Lu-HH1 or lutetium (177Lu) lilotomab satetraxetan (trade name Betalutin). As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway.
- "Lutetium (177lu) lilotomab satetraxetan". Adis Insight. Retrieved 1 September 2016.
- "Recommended INN List 74" (PDF). WHO Drug Information. 29 (3). 2015.
- Robak T, Robak P (2014). "Anti-CD37 antibodies for chronic lymphocytic leukemia". Expert Opin Biol Ther. 14 (5): 651–61. doi:10.1517/14712598.2014.890182. PMID 24555705.
- "EudraCT Number: 2011-000033-36". EU Clinical Trials Registry.
Treatment of lymphoma with targeted internal radiation therapy (Betalutin)
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4): 515. 2014.
- Repetto-Llamazares, A. H.; Larsen, R. H.; Mollatt, C; Lassmann, M; Dahle, J (2013). "Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma". Current radiopharmaceuticals. 6 (1): 20–7. PMC . PMID 23256748.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|